Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer

Filippo Martignano, Cristian Lolli, Giorgia Ravaglia, Valentina Gallà, Giorgia Gurioli, Samanta Salvi

Research output: Contribution to journalArticle

Abstract

Androgen receptor (AR) signaling is deeply involved in prostate cancer (PCa) development and growth, and castration-resistant prostate cancer (CRPC) transformation. Currently, the use of anti-androgen drugs, such as abiraterone and enzalutamide, has temporary effects on CPRC patients due to several patient-related resistance mechanisms, such as the development of AR mutations. Extensive research is being conducted on AR mutations in both tissues and cell free DNA (cfDNA), in order to identify those mutations responsible for treatment resistance. A recent study identified AR mutations in cfDNA samples from CRPC patients treated with different anti-androgen drugs. In particular, these mutations occurred in exon 8, which codes for ligand binding domain (LBD), causing functional protein changes in vitro, leading to anti-androgen drugs resistance. Moreover, a novel drug tested on PCa cell line, VPC-13566, has been proposed as a potentially alternative therapeutic approach in presence of AR-LBD mutations. This evidence underlines the importance of monitoring AR mutations in cfDNA in order to obtain information about the most efficacious treatment and timely therapy switch.

Original languageEnglish
Pages (from-to)S803-S808
JournalTranslational Cancer Research
Volume5
DOIs
Publication statusPublished - 2016

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Mutation
Androgens
Castration
Therapeutics
DNA
Pharmaceutical Preparations
Ligands
Growth and Development
Drug Resistance
Exons
Cell Line
Research
Proteins

Keywords

  • Androgen receptor (AR)
  • Anti-androgen treatment
  • Castration-resistant prostate cancer (CRPC)
  • Cell free DNA (cfDNA)
  • Mutations
  • Prostate cancer (PCa)

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer. / Martignano, Filippo; Lolli, Cristian; Ravaglia, Giorgia; Gallà, Valentina; Gurioli, Giorgia; Salvi, Samanta.

In: Translational Cancer Research, Vol. 5, 2016, p. S803-S808.

Research output: Contribution to journalArticle

@article{0b61501451434a92a0fa8f454bfd66a2,
title = "Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer",
abstract = "Androgen receptor (AR) signaling is deeply involved in prostate cancer (PCa) development and growth, and castration-resistant prostate cancer (CRPC) transformation. Currently, the use of anti-androgen drugs, such as abiraterone and enzalutamide, has temporary effects on CPRC patients due to several patient-related resistance mechanisms, such as the development of AR mutations. Extensive research is being conducted on AR mutations in both tissues and cell free DNA (cfDNA), in order to identify those mutations responsible for treatment resistance. A recent study identified AR mutations in cfDNA samples from CRPC patients treated with different anti-androgen drugs. In particular, these mutations occurred in exon 8, which codes for ligand binding domain (LBD), causing functional protein changes in vitro, leading to anti-androgen drugs resistance. Moreover, a novel drug tested on PCa cell line, VPC-13566, has been proposed as a potentially alternative therapeutic approach in presence of AR-LBD mutations. This evidence underlines the importance of monitoring AR mutations in cfDNA in order to obtain information about the most efficacious treatment and timely therapy switch.",
keywords = "Androgen receptor (AR), Anti-androgen treatment, Castration-resistant prostate cancer (CRPC), Cell free DNA (cfDNA), Mutations, Prostate cancer (PCa)",
author = "Filippo Martignano and Cristian Lolli and Giorgia Ravaglia and Valentina Gall{\`a} and Giorgia Gurioli and Samanta Salvi",
year = "2016",
doi = "10.21037/tcr.2016.10.58",
language = "English",
volume = "5",
pages = "S803--S808",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer

AU - Martignano, Filippo

AU - Lolli, Cristian

AU - Ravaglia, Giorgia

AU - Gallà, Valentina

AU - Gurioli, Giorgia

AU - Salvi, Samanta

PY - 2016

Y1 - 2016

N2 - Androgen receptor (AR) signaling is deeply involved in prostate cancer (PCa) development and growth, and castration-resistant prostate cancer (CRPC) transformation. Currently, the use of anti-androgen drugs, such as abiraterone and enzalutamide, has temporary effects on CPRC patients due to several patient-related resistance mechanisms, such as the development of AR mutations. Extensive research is being conducted on AR mutations in both tissues and cell free DNA (cfDNA), in order to identify those mutations responsible for treatment resistance. A recent study identified AR mutations in cfDNA samples from CRPC patients treated with different anti-androgen drugs. In particular, these mutations occurred in exon 8, which codes for ligand binding domain (LBD), causing functional protein changes in vitro, leading to anti-androgen drugs resistance. Moreover, a novel drug tested on PCa cell line, VPC-13566, has been proposed as a potentially alternative therapeutic approach in presence of AR-LBD mutations. This evidence underlines the importance of monitoring AR mutations in cfDNA in order to obtain information about the most efficacious treatment and timely therapy switch.

AB - Androgen receptor (AR) signaling is deeply involved in prostate cancer (PCa) development and growth, and castration-resistant prostate cancer (CRPC) transformation. Currently, the use of anti-androgen drugs, such as abiraterone and enzalutamide, has temporary effects on CPRC patients due to several patient-related resistance mechanisms, such as the development of AR mutations. Extensive research is being conducted on AR mutations in both tissues and cell free DNA (cfDNA), in order to identify those mutations responsible for treatment resistance. A recent study identified AR mutations in cfDNA samples from CRPC patients treated with different anti-androgen drugs. In particular, these mutations occurred in exon 8, which codes for ligand binding domain (LBD), causing functional protein changes in vitro, leading to anti-androgen drugs resistance. Moreover, a novel drug tested on PCa cell line, VPC-13566, has been proposed as a potentially alternative therapeutic approach in presence of AR-LBD mutations. This evidence underlines the importance of monitoring AR mutations in cfDNA in order to obtain information about the most efficacious treatment and timely therapy switch.

KW - Androgen receptor (AR)

KW - Anti-androgen treatment

KW - Castration-resistant prostate cancer (CRPC)

KW - Cell free DNA (cfDNA)

KW - Mutations

KW - Prostate cancer (PCa)

UR - http://www.scopus.com/inward/record.url?scp=84996912580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996912580&partnerID=8YFLogxK

U2 - 10.21037/tcr.2016.10.58

DO - 10.21037/tcr.2016.10.58

M3 - Article

VL - 5

SP - S803-S808

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

ER -